Inspiration Biopharmaceuticals Articles
Ipsen and Inspiration Biopharma sell IB1001 rights to Cangene
6 February 2013
Ipsen and Inspiration Biopharma in deal with Baxter for OBI-1
24 January 2013
Regulatory briefs from Ipsen/Inspiration, Janssen and Astellas
20 November 2012
Ipsen and Inspiration renegotiate hemophilia agreement
22 August 2012
Inspiration Biopharma earns $35 million milestone from Ipsen on acceptance of hemophilia drug MAA
3 October 2011
Ipsen leaps on strong first-half results; expands links with Inspiration Biopharma and names new CFO
31 August 2011
Ipsen’s partner Inspiration initiates first patient in Phase III pivotal study of OBI-1 for acquired hemophilia A, triggering equity position
22 November 2010
Showing 1-11 of 11 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
